AstraZeneca pledges more Evusheld doses to US, bringing its antibody supply deal to $855M

That was fast: A little more than a month after AstraZeneca sold the U.S. half a million doses of its COVID-19 antibody combo, the British drugmaker and U.S. officials are expanding their supply deal once more.

AZ and the U.S. Department of Health and Human Services have locked up an agreement for a total of 1 million additional doses of AstraZeneca’s long-acting antibody cocktail Evusheld, also known as tixagevimab plus cilgavimab, the company said Monday.